<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of recurrent or metastatic cervical cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of recurrent or metastatic cervical cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of recurrent or metastatic cervical cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jason D Wright, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barbara Goff, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Don S Dizon, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 17, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although uncommon at initial diagnosis, metastatic disease will develop in 15 to 61 percent women with cervical cancer, usually within the first two years of completing treatment [
         <a href="#rid1">
          1,2
         </a>
         ]. In the majority of cases, metastatic cervical cancer is not curable. However, for some patients who present with recurrent disease in the pelvis (locoregional recurrence) or with limited distant metastatic disease, surgical treatment is potentially curative.
        </p>
        <p>
         Histologically, squamous cell carcinoma (SCC), adenocarcinoma, and adenosquamous carcinomas account for approximately 70, 25, and 3 to 5 percent of all cervical cancers, respectively  (
         <a class="graphic graphic_table graphicRef141016" href="/z/d/graphic/141016.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. Rarer histologies include neuroendocrine or small cell carcinomas.
        </p>
        <p>
         The management of recurrent or metastatic cervical cancer will be discussed here. Specific issues regarding patterns of relapse after treatment are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3227.html" rel="external">
          "Invasive cervical cancer: Patterns of recurrence and post-treatment surveillance"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H186822333">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent cervical cancer can present as a local recurrence or as metastatic disease.
        </p>
        <p>
         Locally recurrent cervical cancer usually presents with vaginal symptoms (ie, discharge, bleeding, dyspareunia, or pain). On pelvic exam, a mass or nodularity at the vaginal cuff, which may extend to the pelvic side wall, may be visualized or palpated. Disease within the vagina (or vaginal vault) can be tender to palpation and/or prone to bleed easily.
        </p>
        <p>
         By comparison, patients with metastatic cervical cancer usually present with either no symptoms or nonspecific complaints (ie, fatigue, nausea, or weight loss); however, they may have symptoms related to the site of metastases. As an example, patients with bone metastases present with chronic pain, not alleviated with rest.
        </p>
        <p class="headingAnchor" id="H172229098">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with findings suspicious for recurrence on pelvic exam should undergo a biopsy.
        </p>
        <p>
         Women who present with signs (ie, weight loss, palpable abdominal lesions) or symptoms (ie, pain, nausea, or weight loss) should undergo radiologic imaging to evaluate for metastatic disease. In addition, imaging is essential for women who present with a mass on pelvic exam because the extent of disease will influence the treatment plan.
        </p>
        <p>
         Metastatic cervical cancer may present as nodal disease involving the pelvic, para-aortic, and/or supraclavicular nodes; limited disease involving one organ site; or widely metastatic disease. In one study of over 200 patients, distant metastases, disease limited to the para-aortic nodes, and disease in the supraclavicular nodes (with or without para-aortic node involvement) was found in 65, 22, and 14 percent, respectively [
         <a href="#rid3">
          3
         </a>
         ]. In another review of the literature, the estimated prevalence of organ site involvement by metastatic cervical cancer was [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pelvic or para-aortic nodes (75 and 62 percent, respectively)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lung (33 to 38 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver (33 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peritoneum (5 to 27 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adrenal gland (14 to 16 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intestines (12 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skin (10 percent)
        </p>
        <p>
        </p>
        <p>
         The most commonly used imaging modalities to evaluate recurrent cervical cancer include computed tomography (CT) and positron emission tomography (PET) with or without CT. Of these, we suggest PET/CT for evaluation of local and distant disease. It has a sensitivity of 93 to 96 percent and specificity of 93 to 95 percent [
         <a href="#rid5">
          5
         </a>
         ]. In addition, the results from a PET/CT scan often lead to changes to the therapeutic plan for women with recurrent disease by sparing women from an extensive surgical procedure in the setting of widely metastatic disease [
         <a href="#rid6">
          6-8
         </a>
         ].
        </p>
        <p>
         Patients presenting with isolated metastatic findings on imaging should undergo a biopsy to prove metastatic disease, as there is a risk that these findings may represent a second primary malignancy or a benign process. As an example, in one series of 23 women with cervical cancer who presented with pulmonary lesions and underwent resection, seven (29 percent) were diagnosed with primary lung cancer at final pathologic analysis [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="local">
          'Limited metastatic disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H104509800">
         <span class="h1">
          MANAGEMENT OF LOCAL RECURRENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         For women who present with a local relapse confined to the cervix or vagina, treatment directed to the site of recurrence can be performed with curative intent. Options include hysterectomy or pelvic exenteration in patients who have received prior radiation therapy (RT), or RT in those who have not received RT or are not surgical candidates; the choice depends on the patient's prior treatment.
        </p>
        <p>
         Patients who have previously been treated with RT and who are not candidates for surgical resection should be offered chemotherapy. The approach to these patients is identical to the treatment of women with metastatic disease. (See
         <a class="local">
          'Metastatic disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8642804">
         <span class="h2">
          Candidates for surgical resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who experience a local recurrence should be offered surgical resection with curative intent. Commonly employed criteria to identify those women most likely to benefit from surgery include [
         <a href="#rid10">
          10
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/3227.html" rel="external">
          "Invasive cervical cancer: Patterns of recurrence and post-treatment surveillance", section on 'Patterns of recurrence'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A central pelvic recurrence without side wall fixation or associated hydronephrosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A long disease-free interval
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor size of the recurrence less than 3 cm in diameter
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8642880">
         <span class="h3">
          Surgical procedure
         </span>
        </p>
        <p class="headingAnchor" id="H343518599">
         <span class="h4">
          Following RT with uterine conservation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For women who underwent primary radiation therapy (RT), radical hysterectomy or pelvic exenteration for management of local recurrence is the preferred approach and is associated with five-year survival rates ranging between 30 and 40 percent [
         <a href="#rid11">
          11,12
         </a>
         ]. However, surgical complications are more common in this setting. In one study, 15 of 34 patients who underwent surgery for persistent or recurrent disease following RT experienced major postoperative complications, including fistula formation (in five women).
        </p>
        <p class="headingAnchor" id="H343518606">
         <span class="h4">
          Following hysterectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For women who have undergone hysterectomy (with or without adjuvant RT or chemoradiation), pelvic exenteration represents a potentially curative option for local recurrence or persistent disease. Careful patient selection is required given the perioperative and postoperative morbidity associated with this extensive surgical approach. Vaginectomy, rather than pelvic exenteration, has also been described in select patients [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3190.html" rel="external">
          "Exenteration for gynecologic cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3281.html" rel="external">
          "Vaginectomy"
         </a>
         .)
        </p>
        <p>
         Some patients treated with surgical resection for cervical cancer may benefit from intraoperative radiation therapy (IORT) where it is available. However, the efficacy of IORT has not been shown in prospective trials [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H343518613">
         <span class="h2">
          Nonsurgical options
         </span>
        </p>
        <p class="headingAnchor" id="H8642945">
         <span class="h3">
          Candidates for RT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiation therapy (RT) is a reasonable option for the following patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Women who have not been previously treated with RT
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Women with operable disease who opt not to proceed with pelvic exenteration
        </p>
        <p>
        </p>
        <p>
         The benefit of RT was demonstrated in a single-institution experience of 35 women who were treated with high-dose RT following a pelvic recurrence [
         <a href="#rid16">
          16
         </a>
         ]. The 5- and 10-year survival rates were 43 and 33 percent, respectively, and pelvic control rates were 69 and 62 percent, respectively. The use of brachytherapy and a long treatment-free interval between primary surgery and diagnosis of recurrence were positive predictors of a good outcome.
        </p>
        <p>
         Given the superiority of concomitant chemotherapy with RT (chemoradiation) over RT alone as primary treatment, most experts prefer chemoradiation for these patients. (See
         <a class="medical medical_review" href="/z/d/html/3187.html" rel="external">
          "Management of locally advanced cervical cancer", section on 'Primary chemoradiation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8642960">
         <span class="h3">
          Candidates for chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who are not candidates for surgical resection or salvage RT, chemotherapy is the only option. Chemotherapy has activity for the treatment of cervical cancer, although treatment is less successful if the recurrence is in an area that was previously irradiated. (See
         <a class="local">
          'Initial treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H104509153">
         <span class="h1">
          DISEASE ISOLATED TO THE LYMPH NODES
         </span>
         <span class="headingEndMark">
          —
         </span>
         For women presenting with disease limited to the nodes (para-aortic and/or supraclavicular nodes), the prognosis is poor. This was illustrated in a retrospective study of 375 patients with recurrent cervical cancer [
         <a href="#rid3">
          3
         </a>
         ]. The rate of overall survival (OS) at five years was 27 and 0 percent for women with limited metastatic disease involving the para-aortic nodes (n = 60) or the supraclavicular nodes (n = 26) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         There are limited data to help guide treatment of women with metastatic disease limited to the lymph nodes. Some experts prefer systemic chemotherapy, while others prefer RT (with or without chemotherapy). The choice between treatments depends on institutional practice and patient preference. (See
         <a class="local">
          'Initial treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H104508737">
         <span class="h1">
          LIMITED METASTATIC DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with limited metastatic disease (ie, disease in the para-aortic nodes or solitary lung metastasis), treatment can be directed towards the area of recurrence using radiation therapy (RT) or, in selected cases, a surgical approach.
        </p>
        <p>
         In selected patients who present with limited metastatic disease, resection may be feasible. As an example, in one series of 15 women who underwent resection of pulmonary metastases for cervical cancer, 13 were alive with a median follow-up of 18 months (range, 4 to 68 months) [
         <a href="#rid9">
          9
         </a>
         ]. The short interval of follow-up and lack of historical controls (that received chemotherapy, for example) limits interpretation of this approach. Given the potential morbidity associated with resection, careful selection of patients is required. (See
         <a class="medical medical_review" href="/z/d/html/2796.html" rel="external">
          "Surgical resection of pulmonary metastases: Outcomes by histology", section on 'Gynecologic cancers'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7815.html" rel="external">
          "Surgical resection of pulmonary metastases: Benefits, indications, preoperative evaluation, and techniques"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H104509204">
         <span class="h1">
          METASTATIC DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         For the majority of patients with metastatic disease and those who are not candidates for a local treatment approach, we administer chemotherapy. For women being treated in the first-line setting, we administer chemotherapy plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         rather than chemotherapy alone. Treatment incorporating bevacizumab was shown to improve OS in these patients. (See
         <a class="local">
          'Initial treatment'
         </a>
         below.)
        </p>
        <p>
         There are several agents with activity in cervical cancer, which can be used as part of a combination regimen or as single-agent therapy.
        </p>
        <p>
         Treatment for metastatic cervical cancer can be stratified on whether or not prior chemotherapy was administered. This stratification is based on a retrospective evaluation by the Gynecologic Oncology Group (GOG) that included 428 patients treated on first-line chemotherapy trials [
         <a href="#rid17">
          17
         </a>
         ]. The following individuals had a higher likelihood of a poor response to cisplatin-based combination chemotherapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Black people (versus non-Black people) – odds ratio (OR) for poor response 0.49 (95% CI 0.28-0.83)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Those with performance status 1 or 2 (versus 0) – OR 0.60 (95% CI 0.38-0.94)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Those with pelvic disease (versus nonpelvic location) – OR 0.58 (95% CI 0.38-0.90)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Those with prior treatment with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         as part of chemoradiation (versus none) – OR 0.52 (95% CI 0.32-0.85)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Those with recurrence within one year of diagnosis (versus longer) – OR 0.61 (95% CI 0.39-0.95)
        </p>
        <p>
        </p>
        <p>
         These data were used to construct a prognostic model to predict treatment response to cisplatin-based chemotherapy by identifying three risk groups: high-risk (four to five factors present), mid-risk (two to three factors present), and low-risk (zero to one factor present). This model was externally validated in a separate group of patients treated on a separate GOG trial with the following results [
         <a href="#rid17">
          17
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High-risk group – The overall response rate (ORR) was 14 percent, median progression-free survival (PFS) was 3 months, and median OS was 5.6 months
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mid-risk group – ORR 29 percent, PFS 4 months, OS 7.6 months
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low-risk group – ORR 43 percent, PFS 7 months, OS 12 months
        </p>
        <p>
        </p>
        <p>
         This model suggests that chemotherapy-naive patients have a higher response rate than women who received prior chemotherapy, including as part of chemoradiation [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
         For patients with metastatic, advanced, or recurrent cervical cancer who are candidates for chemotherapy,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         is the most widely used agent [
         <a href="#rid20">
          20
         </a>
         ]. However, there are no randomized trials comparing single-agent cisplatin with other single agents (eg,
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         ,
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         , or
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         ). The approach to chemotherapy in the first- and later-line treatment setting is reviewed below.
        </p>
        <p class="headingAnchor" id="H2177909474">
         <span class="h2">
          Initial treatment
         </span>
        </p>
        <p class="headingAnchor" id="H2175837618">
         <span class="h3">
          Components of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         For women with recurrent, metastatic, or advanced cervical cancer, we recommend treatment consisting of a platinum-based combination plus the angiogenesis inhibitor,
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , and an immune checkpoint inhibitor. However, the costs of therapy may require scrutiny in comparison to the benefits and risks of incorporating bevacizumab or immune checkpoint inhibitors in this setting, especially in low-resource settings. (See
         <a class="local">
          'Addition of a checkpoint inhibitor'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1225233361">
         <span class="h3">
          Combination chemotherapy, as backbone
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the first-line setting we suggest a platinum-based combination. In addition, the data support the use of a platinum-based combination rather than single-agent
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         . Our preferred combination is cisplatin plus
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         rather than other cisplatin-based regimens. This recommendation is based on the data below (see
         <a class="local">
          'Combination versus single-agent therapy'
         </a>
         below):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The GOG 240 trial randomly assigned 452 women with metastatic cervical cancer to
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         or to paclitaxel plus
         <a class="drug drug_general" data-topicid="10007" href="/z/d/drug information/10007.html" rel="external">
          topotecan
         </a>
         with a second randomization to treatment with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         [
         <a href="#rid21">
          21
         </a>
         ]. Treatment with paclitaxel plus topotecan (with or without bevacizumab) resulted in:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A significantly higher risk of progression compared with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         (median PFS, 5.7 versus 7.6 months, respectively; HR 1.39, 95% CI 1.09-1.77)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No significant impact on OS (median, 12.5 versus 15 months; HR 1.20, 99% CI 0.82-1.76)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The administration of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         for these women is discussed above. (See
         <a class="local">
          'Initial treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The GOG 204 enrolled 434 patients with metastatic or advanced cervical cancer and randomly assigned them to treatment with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         (the reference control arm) or one of three experimental regimens (cisplatin plus
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         , cisplatin plus
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         , or cisplatin plus
         <a class="drug drug_general" data-topicid="10007" href="/z/d/drug information/10007.html" rel="external">
          topotecan
         </a>
         ) with the following results [
         <a href="#rid22">
          22
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There was no difference in response rates – For
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         , the ORR was 29 percent. The ORR was 26, 22, and 23 percent for cisplatin administered with
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         , or
         <a class="drug drug_general" data-topicid="10007" href="/z/d/drug information/10007.html" rel="external">
          topotecan
         </a>
         , respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There was no difference in the risk of death among any of the experimental regimens compared with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          Cisplatin
         </a>
         plus
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         resulted in much less serious febrile neutropenia compared with cisplatin in combination with
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         ,
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         , or
         <a class="drug drug_general" data-topicid="10007" href="/z/d/drug information/10007.html" rel="external">
          topotecan
         </a>
         (6 versus 13, 14, and 10 percent), respectively. However, cisplatin plus paclitaxel resulted in less serious thrombocytopenia compared with the other arms (7 versus 8, 28, and 35 percent for cisplatin plus vinorelbine, gemcitabine, or topotecan, respectively).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1639880214">
         <span class="h4">
          Alternate use of carboplatin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of the toxicity seen with cisplatin-based combination chemotherapy,
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         is a reasonable substitute for
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         , particularly for patients with medical comorbidities (eg, pre-existing renal failure) and those patients previously treated with cisplatin-based chemoradiation. This is based on the results of the Japanese Clinical Oncology Group 0505 trial (JCOG 0505) [
         <a href="#rid23">
          23
         </a>
         ]. In JCOG 0505, 253 women with stage IVB, persistent or recurrent cervical cancer were randomly assigned treatment with cisplatin (50 mg/m
         <sup>
          2
         </sup>
         ) plus
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         (135 mg/m
         <sup>
          2
         </sup>
         ) or carboplatin (area under curve [AUC] 5) plus paclitaxel (175 mg/m
         <sup>
          2
         </sup>
         ), administered every three weeks for six cycles. Prior cisplatin therapy (primarily with chemoradiation) was noted in 43 and 50 percent of each group, respectively. Compared with cisplatin plus paclitaxel, treatment with carboplatin and paclitaxel resulted in:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar ORR (63 versus 60 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No difference in OS (HR for mortality 0.99, 90% CI 0.79-1.25).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significantly less serious (grade 4) neutropenic events (45 versus 75 percent, p &lt;0.0001). There were also less serious (grade 3/4) incidences of renal insufficiency (0 versus 2.4 percent), nausea, and vomiting (3 versus 7 percent). However,
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         resulted in more thrombocytopenia (25 versus 3 percent) and sensory neuropathy (5 versus 0 percent).
        </p>
        <p>
        </p>
        <p>
         A post-hoc analysis showed that prior platinum exposure may impact outcomes such that those women not previously treated with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         had a lower OS when
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         was combined with
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         rather than cisplatin (median, 13 versus 23 months; HR 0.69, 95% CI 0.47-1.02). There was no statistically significant difference among women who were previously treated with cisplatin (HR 0.69, 95% CI 0.47-1.02).
        </p>
        <p>
         The results of JCOG 0505 establish
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         as a reasonable alternative to
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         plus paclitaxel in the treatment of women with metastatic cervical cancer, particularly in those who are not candidates for cisplatin and/or were previously treated with cisplatin-based chemoradiation. A 2014 systematic review including 1181 patients similarly found that carboplatin was a reasonable alternative to cisplatin [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1639879582">
         <span class="h4">
          Combination versus single-agent therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evidence to support the use of a platinum-based combination rather than single-agent therapy is limited. However, combination therapy was compared against single-agent
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         in a 2012 meta-analysis that included five randomized trials (n = 1114) [
         <a href="#rid25">
          25
         </a>
         ]. Compared with combination platinum-based therapy, single-agent cisplatin resulted in a lower response rate (relative risk [RR] 0.60, 95% CI 0.44-0.81) but was associated with less toxicity, including less serious (grade 3/4) neutropenia (RR 0.04, 95% CI 0.02-0.12), and thrombocytopenia (RR 0.16, 95% CI 0.05-0.48).
        </p>
        <p>
         In two trials, the combination of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         resulted in OS ranging from 13 to 15 months and PFS from 6 to 8 months. In contrast, OS ranged from 7 to 9 months and PFS was approximately three months with cisplatin alone (&gt;11 trials).
        </p>
        <p class="headingAnchor" id="H3473311414">
         <span class="h3">
          Addition of bevacizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incorporation of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         is based on the results of GOG 240, in which 452 women with metastatic, persistent, or recurrent cervical carcinoma were randomly assigned to chemotherapy with or without bevacizumab. Previous platinum-based therapy was administered with RT in 75 and 74 percent of patients, respectively. Final results (the prespecified cutoff for final analysis [348 deaths] occurred) were nearly identical to the results reported after a 2012 interim analysis [
         <a href="#rid21">
          21,26
         </a>
         ]. Chemotherapy plus bevacizumab resulted in:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A significant improvement in OS compared with chemotherapy alone (median, 16.8 versus 13.3 months, respectively; hazard ratio [HR] 0.77, 98% CI 0.62-0.95).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         OS in women who did not receive prior RT was higher in both groups (24.5 versus 16.8 months).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Post-progression survival was not significantly different across groups (8.4 versus 7.1 months; HR 0.83, 95% CI 0.66-1.05).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A significant improvement in PFS (median, 8.2 versus 6.0 months; HR 0.68, 95% CI 0.54-0.82).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A significant improvement in the ORR (49 versus 36 percent).
        </p>
        <p>
        </p>
        <p>
         Treatment with
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         resulted in a significantly increased rate of grade 2 or greater hypertension, defined as systolic 160 to 179 mmHg and/or diastolic 100 to 109 mmHg (25 versus 2 percent; risk ratio [RR] 13.8, 95% CI 5.1-37). Other serious (grade 3/4) toxicities included: gastrointestinal fistula (3 versus 0 percent); genitourinary fistula (3 versus &lt;1 percent); neutropenia (36 versus 26 percent; RR 1.4, 95% CI 1.0-1.8); and thrombosis or embolism (8 versus 2 percent; RR 4.5, 95% CI 1.6-13). There was no difference in quality of life reported at up to nine months following the start of therapy [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Taken together, these results support the use of chemotherapy plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         as a first-line treatment of metastatic cervical cancer, and in August 2014, bevacizumab received approval for this indication by the US Food and Drug Administration and the United Kingdom Cancer Drug Fund. The choice of the chemotherapy partner is discussed above. (See
         <a class="local">
          'Combination chemotherapy, as backbone'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H839207583">
         <span class="h3">
          Addition of a checkpoint inhibitor
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with metastatic cervical cancer or recurrent cervical cancer not amenable to curative localized therapies, we recommend addition of either
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         (irrespective of programmed cell death ligand 1 [PD-L1] status) or
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (for PD-L1 positive disease only). The choice between atezolizumab and pembrolizumab in PD-L1 positive disease should be made based on cost and availability, given a lack of direct comparisons of these two agents in this setting.
        </p>
        <p class="headingAnchor" id="H16060198">
         <span class="h4">
          Atezolizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         The addition of
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         to platinum-based chemotherapy and
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         has shown OS improvements in this setting, regardless of PD-L1 status.
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          Pembrolizumab
         </a>
         is another option for PD-L1 positive disease only and is discussed below. (See
         <a class="local">
          'Pembrolizumab, as another option for PD-L1 positive disease'
         </a>
         below.)
        </p>
        <p>
         In an open-label randomized trial in 410 patients with metastatic or recurrent cervical cancer not amenable to curative treatment, the addition of
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         to platinum-paclitaxel chemotherapy and
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         improved both median PFS (13.7 versus 10.4 months; HR 0.62, 95% CI 0.49-0.78) and OS (32 versus 23 months; HR 0.68, 95% CI 0.52-0.88) at a median follow-up of 33 months [
         <a href="#rid28">
          28
         </a>
         ]. Grade ≥3 events occurred in 79 percent receiving atezolizumab and 75 percent in the control group.
        </p>
        <p>
         Although this approach does not yet have regulatory approval, we consider it to be an appropriate strategy based on these published results.
        </p>
        <p class="headingAnchor" id="H4063265053">
         <span class="h4">
          Pembrolizumab, as another option for PD-L1 positive disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients whose cancers have PD-L1 expression combined positive score (CPS) ≥1, the addition of
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         to chemotherapy and
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         has shown OS improvements and has regulatory approval in the US [
         <a href="#rid29">
          29
         </a>
         ]. Either pembrolizumab or
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         may be used in patients with PD-L1 positive disease. Atezolizumab is discussed above. (See
         <a class="local">
          'Atezolizumab'
         </a>
         above.)
        </p>
        <p>
         In a phase III trial in 617 patients receiving first-line chemotherapy for persistent, recurrent, or metastatic cervical cancer (approximately two-thirds of whom also received
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         ), the addition of
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         improved median PFS versus placebo (10.4 versus 8.2 months; HR for disease progression or death 0.65, 95% CI 0.53-0.79), without negatively impacting health-related quality of life [
         <a href="#rid30">
          30,31
         </a>
         ]. Objective response rates were 66 and 51 percent, respectively.
        </p>
        <p>
         Benefits were similar between the overall population, in the patients who had received
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         and those who did not, and in those with PD-L1 CPS of ≥1 as well as those with CPS ≥10. At longer follow up of a median of 39 months, addition of
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         to chemotherapy improved median OS in the overall group (26 versus 17 months), among those with CPS ≥1 (29 versus 17 months), and among those with CPS ≥10 (30 versus 17 months) [
         <a href="#rid32">
          32
         </a>
         ]. However, only a small number of patients had CPS &lt;1 (69 patients), and it remains unclear if this group benefits from the addition of pembrolizumab (HR for OS 0.87, 95% CI 0.50-1.52).
        </p>
        <p>
         The most common grade 3 to 5 adverse events were anemia (30 percent in the
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         group and 27 percent in the placebo group) and neutropenia (12 and 10 percent, respectively). Toxicities of immune checkpoint inhibitors are discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors"
         </a>
         .)
        </p>
        <p>
         Based on these data,
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         is approved by the US Food and Drug Administration (FDA) in combination with chemotherapy, with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H85099849">
         <span class="h2">
          Second-line therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For women who have progressed after first-line treatment and those patients who are not candidates for combination chemotherapy, we suggest single-agent therapy. However, there is no evidence that treatment in the second- or later-line setting improves OS compared with best supportive care in this population.
        </p>
        <p>
         A choice among active agents must be tailored to the individual patient, with consideration to prior therapies received, residual toxicity, and performance status. For those who have progressed on prior chemotherapy for metastatic disease and desire further treatment, we assess tumor PD-L1 expression on existing tissue for consideration of
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (or consider repeat biopsy, if tissue is not available). For women whose tumors display PD-L1 expression, pembrolizumab may reasonably be offered before additional cytotoxic therapy, provided it was not used in the front-line setting. Given the limited activity of currently available agents, we encourage participation in well-designed clinical trials exploring alternative approaches to metastatic cervical cancer.
        </p>
        <p>
         The most active single agents are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carboplatin
         </strong>
         – ORR 15 percent [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Paclitaxel
         </strong>
         (175 mg/m
         <sup>
          2
         </sup>
         intravenous [IV] every three weeks with dose reduction to 135 mg/m
         <sup>
          2
         </sup>
         if patients received prior RT) – ORR 20 to 25 percent [
         <a href="#rid35">
          35-37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topotecan
         </strong>
         (1.5 mg/m
         <sup>
          2
         </sup>
         IV daily for five days every 21 days) – ORR 19 percent [
         <a href="#rid38">
          38-41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tisotumab
         </strong>
         (2 mg/kg IV every three weeks) – Tisotumab vedotin-tftv is a tissue factor-directed antibody and microtubule inhibitor drug conjugate approved by the US Food and Drug Administration (FDA) for recurrent or metastatic cervical cancer that has progressed on chemotherapy [
         <a href="#rid42">
          42
         </a>
         ]. In a single-arm trial that treated 101 patients with recurrent or metastatic cervical cancer who had received no more than two prior systemic regimens in the recurrent or metastatic setting, including at least one prior platinum-based chemotherapy regimen, the ORR to tisotumab was 24 percent (17 percent partial response and 7 percent complete response) [
         <a href="#rid43">
          43
         </a>
         ]. The most common treatment-related adverse events included alopecia (38 percent), epistaxis (30 percent), nausea (27 percent), conjunctivitis (26 percent), fatigue (26 percent), and dry eye (23 percent). Grade ≥3 treatment-related adverse events were reported in 28 percent of patients and included neutropenia (3 percent), fatigue (2 percent), ulcerative keratitis (2 percent), and peripheral neuropathies (2 percent each with sensory, motor, sensorimotor, and neuropathy peripheral). (See
         <a class="medical medical_review" href="/z/d/html/96203.html" rel="external">
          "Ocular side effects of systemically administered chemotherapy", section on 'Antibody-drug conjugates'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Checkpoint inhibitors
         </strong>
         – Immune checkpoint inhibitors are an option for those who have not received them in a prior line of treatment.
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          Pembrolizumab
         </a>
         (200 mg IV every three weeks) has a role in the first-line setting for metastatic cervical cancers, but it may be used in the second-line setting for those with PD-L1 CPS ≥1 percent, per the FDA [
         <a href="#rid44">
          44
         </a>
         ].
         <a class="drug drug_general" data-topicid="119172" href="/z/d/drug information/119172.html" rel="external">
          Cemiplimab
         </a>
         (350 mg IV every three weeks) has also demonstrated efficacy in platinum-resistant recurrent cervical cancer that was not previously treated with immunotherapy (irrespective of PD-L1 expression). It does not have regulatory approval for cervical cancer, however. (See
         <a class="local">
          'Addition of a checkpoint inhibitor'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For cervical cancers that were not treated initially with
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         , it has shown promise as second-line therapy in PD-L1-positive cancers [
         <a href="#rid44">
          44
         </a>
         ]. For example, in a phase II basket study of pembrolizumab, among 82 patients with advanced, pretreated cervical cancer and PD-L1 expression of 1 percent or more, the ORR was 15 percent [
         <a href="#rid45">
          45
         </a>
         ]. Similar findings were observed in the KEYNOTE-028 trial, in which the ORR was 17 percent and duration of response was 5.4 months [
         <a href="#rid46">
          46
         </a>
         ]. Responses in tumors with high mutational burden are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">
          "Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Tumors with high mutational burden'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a randomized trial in patients with disease progression after platinum-based chemotherapy,
         <a class="drug drug_general" data-topicid="119172" href="/z/d/drug information/119172.html" rel="external">
          cemiplimab
         </a>
         improved OS relative to single-agent chemotherapy (12.0 versus 8.5 months; HR 0.69, 95% CI 0.56-0.84), as well as objective response rates (16 versus 6 percent) [
         <a href="#rid47">
          47
         </a>
         ]. Cemiplimab versus chemotherapy resulted in a median PFS of 2.8 and 2.9 months, respectively, but cemiplimab increased duration of response (16.4 versus 6.9 months).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         PD-L1 expression was assessed using the SP263 monoclonal antibody (Ventana). Patients with cancers that were PD-L1 positive (expression on ≥1 percent of tumor cells) experienced similar clinical outcomes as the overall population. Grade ≥3 events occurred in 45 percent in the
         <a class="drug drug_general" data-topicid="119172" href="/z/d/drug information/119172.html" rel="external">
          cemiplimab
         </a>
         group and 53 percent in the chemotherapy group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Toxicities of checkpoint inhibitors include rash, colitis, and pneumonitis, among others, and are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other less frequently used options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nanoparticle, albumin-bound
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         (125 mg/m
         <sup>
          2
         </sup>
         on days 1, 8, and 15 every 28 days) – ORR 29 percent [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          Vinorelbine
         </a>
         (30 mg/m
         <sup>
          2
         </sup>
         IV push weekly for two weeks every 21 days) – ORR 15 percent [
         <a href="#rid49">
          49-51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          Pemetrexed
         </a>
         (900 mg/m
         <sup>
          2
         </sup>
         IV every three weeks) – ORR 15 percent [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          Ifosfamide
         </a>
         (1.2 g/m
         <sup>
          2
         </sup>
         IV daily for five days every 28 days) – ORR 22 percent [
         <a href="#rid38">
          38,54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          Irinotecan
         </a>
         (350 mg/m
         <sup>
          2
         </sup>
         IV every three weeks, or 125 mg/m
         <sup>
          2
         </sup>
         weekly for four weeks followed by a two-week washout period) – ORR 15 percent [
         <a href="#rid55">
          55,56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          MANAGEMENT OF ACUTELY SYMPTOMATIC PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         For women with pelvic pain or bleeding from locally advanced disease, and for patients with symptomatic metastatic disease, single-dose or short-course external beam radiation therapy (RT) may be useful. However, treatment planning is critical for women who have previously been treated with RT due to the risks of excessive toxicity to normal tissue [
         <a href="#rid57">
          57-60
         </a>
         ]. For women with symptoms from a vaginal or pelvic recurrence, the optimal regimen has not been established. A typical regimen consists of twice daily fractionations of external beam RT (3.7 Gy per fraction) for two consecutive days repeated at four-week intervals for three courses [
         <a href="#rid57">
          57,60
         </a>
         ].
        </p>
        <p>
         For the treatment of visceral or distant metastases, large fractions of RT administered in a short treatment course may also be used for local treatment of symptoms related to metastatic disease, such as alleviation of pain from skeletal metastases, or symptoms associated with brain lesions. (See
         <a class="medical medical_review" href="/z/d/html/2805.html" rel="external">
          "Radiation therapy for the management of painful bone metastases"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5217.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of brain metastases"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3938927270">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113940.html" rel="external">
          "Society guideline links: Treatment of cervical cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Introduction
         </strong>
         – Following treatment of early-stage cervical cancer, distant metastases or multiple recurrence sites develop in 15 to 61 percent of cases, usually within the first two years of completing treatment. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Recurrent cervical cancer presents as disease isolated to the pelvis (locoregional recurrence) or with disease involving other organs or outside the pelvis. If a vaginal recurrence is suspected, the area of concern should be biopsied to prove recurrent disease. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         All patients suspected of recurrent disease should undergo positron emission tomography (PET)/computed tomography (CT) for evaluation of local and distant disease. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of local recurrence
         </strong>
         – For patients with a local recurrence, we suggest surgical resection, rather than nonsurgical approaches, if they are appropriate surgical candidates based on tumor recurrence, age, and comorbidities (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In select patients, surgical resection may present a curative option. However, for patients with a local recurrence who have not received radiation therapy (RT), RT in combination with chemotherapy is an acceptable alternative, and is preferred in those who are not surgical candidates, provided they have not previously undergone pelvic or intravaginal RT. (See
         <a class="local">
          'Management of local recurrence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease limited to the nodes
         </strong>
         – For women presenting with disease limited to the nodes (ie, para-aortic and/or supraclavicular nodes), some experts prefer to treat with systemic chemotherapy. Others prefer to administer RT (with or without chemotherapy). A choice between them depends on institutional practice and patient preferences.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Isolated metastatic disease
         </strong>
         – For women presenting with isolated metastatic disease (ie, to the lung or liver), we suggest surgical resection if they are appropriate candidates (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). These patients may achieve a sustained clinical remission following resection of disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other metastatic disease
         </strong>
         – For women with recurrent cervical cancer, those who are not surgical candidates, and those who present with metastatic disease, our approach is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We suggest first-line treatment with chemotherapy plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         rather than chemotherapy alone (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). However, the costs of therapy may require scrutiny in comparison to the benefits and risks of incorporating bevacizumab in this setting, especially in low-resource settings. (See
         <a class="local">
          'Initial treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We also recommend the addition of either
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         (irrespective of programmed cell death ligand 1 [PD-L1] status) or
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (for PD-L1 positive disease only) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). The choice between atezolizumab and pembrolizumab in PD-L1 positive disease should be made based on cost and availability, given a lack of direct comparisons of these two agents in this setting. (See
         <a class="local">
          'Addition of a checkpoint inhibitor'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We suggest a platinum-based combination rather than a nonplatinum-based regimen or single-agent
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). We suggest cisplatin plus
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         rather than other platinum-based regimens (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          Carboplatin
         </a>
         plus paclitaxel is a reasonable alternative, particularly for patients who are poor candidates for cisplatin (eg, due to pre-existing renal failure) and patients previously treated with cisplatin-based chemoradiation. (See
         <a class="local">
          'Initial treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Second-line therapy
         </strong>
         – For patients who progress following first-line chemotherapy and those who are not candidates for combination therapy, we suggest single-agent therapy. A choice among active agents must be tailored to the individual patient, with consideration to prior therapies received, residual toxicity, and performance status. (See
         <a class="local">
          'Second-line therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Special consideration for vaginal metastases
         </strong>
         – For patients who are symptomatic due to vaginal metastases or other lesions, we suggest RT for palliation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Management of acutely symptomatic patients'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975 to 2003. National Cancer Institute, Bethesda, MD 2006.
         </li>
         <li class="breakAll">
          Surveillance, Epidemiology, and End Results. SEER registry data, 2000 to 2004. http://seer.cancer.gov/ (Accessed on April 25, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong JH, Tsai CS, Lai CH, et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 2004; 60:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fulcher AS, O'Sullivan SG, Segreti EM, Kavanagh BD. Recurrent cervical carcinoma: typical and atypical manifestations. Radiographics 1999; 19 Spec No:S103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel CN, Nazir SA, Khan Z, et al. 18F-FDG PET/CT of cervical carcinoma. AJR Am J Roentgenol 2011; 196:1225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung HH, Jo H, Kang WJ, et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007; 104:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pallardy A, Bodet-Milin C, Oudoux A, et al. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging 2010; 37:1270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Veldt AA, Buist MR, van Baal MW, et al. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET. J Nucl Med 2008; 49:1936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim MC, Lee HS, Seo SS, et al. Pathologic diagnosis and resection of suspicious thoracic metastases in patients with cervical cancer through thoracotomy or video-assisted thoracic surgery. Gynecol Oncol 2010; 116:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedlander M, Grogan M, U.S. Preventative Services Task Force. Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist 2002; 7:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutledge S, Carey MS, Prichard H, et al. Conservative surgery for recurrent or persistent carcinoma of the cervix following irradiation: is exenteration always necessary? Gynecol Oncol 1994; 52:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maneo A, Landoni F, Cormio G, et al. Radical hysterectomy for recurrent or persistent cervical cancer following radiation therapy. Int J Gynecol Cancer 1999; 9:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vizzielli G, Tortorella L, Conte C, et al. Is a Vaginectomy Enough or is a Pelvic Exenteration Always Required for Surgical Treatment of Recurrent Cervical Cancer? A Propensity-Matched Study. Ann Surg Oncol 2021; 28:3281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barney BM, Petersen IA, Dowdy SC, et al. Intraoperative Electron Beam Radiotherapy (IOERT) in the management of locally advanced or recurrent cervical cancer. Radiat Oncol 2013; 8:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-Monge R, Jurado M, Aristu JJ, et al. Intraoperative electron beam radiotherapy during radical surgery for locally advanced and recurrent cervical cancer. Gynecol Oncol 2001; 82:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haasbeek CJ, Uitterhoeve AL, van der Velden J, et al. Long-term results of salvage radiotherapy for the treatment of recurrent cervical carcinoma after prior surgery. Radiother Oncol 2008; 89:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore DH, Tian C, Monk BJ, et al. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2010; 116:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long HJ 3rd. Management of metastatic cervical cancer: review of the literature. J Clin Oncol 2007; 25:2966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Movva S, Rodriguez L, Arias-Pulido H, Verschraegen C. Novel chemotherapy approaches for cervical cancer. Cancer 2009; 115:3166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gadducci A, Tana R, Cosio S, Cionini L. Treatment options in recurrent cervical cancer (Review). Oncol Lett 2010; 1:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009; 27:4649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. J Clin Oncol 2015; 33:2129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorusso D, Petrelli F, Coinu A, et al. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol 2014; 133:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scatchard K, Forrest JL, Flubacher M, et al. Chemotherapy for metastatic and recurrent cervical cancer. Cochrane Database Syst Rev 2012; 10:CD006469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017; 390:1654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penson RT, Huang HQ, Wenzel LB, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol 2015; 16:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oaknin A, Gladieff L, Martínez-García J, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet 2024; 403:31.
          </a>
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125514s147lbl.pdf (Accessed on January 16, 2024).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med 2021; 385:1856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monk BJ, Tewari KS, Dubot C, et al. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2023; 24:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monk BJ, Colombo N, Tewari KS, et al. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. J Clin Oncol 2023; 41:5505.
          </a>
         </li>
         <li class="breakAll">
          KEYTRUDA (pembrolizumab) injection, for intravenous use. United States Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf (Accessed on June 07, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss GR, Green S, Hannigan EV, et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol 1990; 39:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996; 14:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtin JP, Blessing JA, Webster KD, et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2001; 19:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kudelka AP, Winn R, Edwards CL, et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 1997; 8:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thigpen T. The role of chemotherapy in the management of carcinoma of the cervix. Cancer J 2003; 9:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bookman MA, Blessing JA, Hanjani P, et al. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000; 77:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muderspach LI, Blessing JA, Levenback C, Moore JL Jr. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2001; 81:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Rustum NR, Lee S, Massad LS. Topotecan for recurrent cervical cancer after platinum-based therapy. Int J Gynecol Cancer 2000; 10:285.
          </a>
         </li>
         <li class="breakAll">
          Tisotumab vedotin-tftv for injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761208s000lbl.pdf (Accessed on September 22, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021; 22:609.
          </a>
         </li>
         <li class="breakAll">
          Pembrolizumab injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s071s090lbl.pdf (Accessed on June 18, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung HC, Ros W, Delord JP, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2019; 37:1470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frenel JS, Le Tourneau C, O'Neil B, et al. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol 2017; 35:4035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tewari KS, Monk BJ, Vergote I, et al. Survival with Cemiplimab in Recurrent Cervical Cancer. N Engl J Med 2022; 386:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alberts DS, Blessing JA, Landrum LM, et al. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecol Oncol 2012; 127:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris M, Brader KR, Levenback C, et al. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1998; 16:1094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacava JA, Leone BA, Machiavelli M, et al. Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol 1997; 15:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muggia FM, Blessing JA, Method M, et al. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller DS, Blessing JA, Bodurka DC, et al. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2008; 110:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorusso D, Ferrandina G, Pignata S, et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol 2010; 21:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutton GP, Blessing JA, DeMars LR, et al. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol 1996; 63:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lhommé C, Fumoleau P, Fargeot P, et al. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1999; 17:3136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Look KY, Blessing JA, Levenback C, et al. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 1998; 70:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spanos W Jr, Guse C, Perez C, et al. Phase II study of multiple daily fractionations in the palliation of advanced pelvic malignancies: preliminary report of RTOG 8502. Int J Radiat Oncol Biol Phys 1989; 17:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onsrud M, Hagen B, Strickert T. 10-Gy single-fraction pelvic irradiation for palliation and life prolongation in patients with cancer of the cervix and corpus uteri. Gynecol Oncol 2001; 82:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halle JS, Rosenman JG, Varia MA, et al. 1000 cGy single dose palliation for advanced carcinoma of the cervix or endometrium. Int J Radiat Oncol Biol Phys 1986; 12:1947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Lonkhuijzen L, Thomas G. Palliative radiotherapy for cervical carcinoma, a systematic review. Radiother Oncol 2011; 98:287.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3185 Version 56.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975 to 2003. National Cancer Institute, Bethesda, MD 2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="http://seer.cancer.gov/" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Surveillance, Epidemiology, and End Results. SEER registry data, 2000 to 2004. http://seer.cancer.gov/ (Accessed on April 25, 2011).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15337563" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Recurrent squamous cell carcinoma of cervix after definitive radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10517448" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Recurrent cervical carcinoma: typical and atypical manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21512096" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : 18F-FDG PET/CT of cervical carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17049971" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20306032" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18997039" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19889448" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pathologic diagnosis and resection of suspicious thoracic metastases in patients with cervical cancer through thoracotomy or video-assisted thoracic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12185296" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Guidelines for the treatment of recurrent and metastatic cervical cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8157192" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Conservative surgery for recurrent or persistent carcinoma of the cervix following irradiation: is exenteration always necessary?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11240782" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Radical hysterectomy for recurrent or persistent cervical cancer following radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33063258" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Is a Vaginectomy Enough or is a Pelvic Exenteration Always Required for Surgical Treatment of Recurrent Cervical Cancer? A Propensity-Matched Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23566444" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Intraoperative Electron Beam Radiotherapy (IOERT) in the management of locally advanced or recurrent cervical cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11520152" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Intraoperative electron beam radiotherapy during radical surgery for locally advanced and recurrent cervical cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18237803" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Long-term results of salvage radiotherapy for the treatment of recurrent cervical carcinoma after prior surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19853287" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17617528" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Management of metastatic cervical cancer: review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19452541" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Novel chemotherapy approaches for cervical cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22966247" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Treatment options in recurrent cervical cancer (Review).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24552320" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Improved survival with bevacizumab in advanced cervical cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19720909" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25732161" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24486604" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23076924" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Chemotherapy for metastatic and recurrent cervical cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28756902" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25638326" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38048793" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38048793" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34534429" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36878237" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37910822" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37910822" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2258080" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8622025" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11230468" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9311440" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14690318" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The role of chemotherapy in the management of carcinoma of the cervix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10831357" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11354055" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11240688" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Topotecan for recurrent cervical cancer after platinum-based therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11240688" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Topotecan for recurrent cervical cancer after platinum-based therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33845034" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33845034" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30943124" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29095678" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35139273" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Survival with Cemiplimab in Recurrent Cervical Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22986144" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9508195" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9053483" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14766259" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18455781" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19605508" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8898163" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10506610" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9790784" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2476426" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Phase II study of multiple daily fractionations in the palliation of advanced pelvic malignancies: preliminary report of RTOG 8502.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11426980" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : 10-Gy single-fraction pelvic irradiation for palliation and life prolongation in patients with cancer of the cervix and corpus uteri.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2429945" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : 1000 cGy single dose palliation for advanced carcinoma of the cervix or endometrium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21316785" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Palliative radiotherapy for cervical carcinoma, a systematic review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
